Photophobia

17 registered clinical trials studyying Photophobia — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Light Exposure, Migraine Outcomes, and Sleep Quality NCT07476053	Arizona State University	N/A
Not Yet Recruiting	Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity NCT07223086	University of Alabama at Birmingham	N/A
Recruiting	Comparison Between Spectacles and Contact Lenses NCT06905912	University of Oklahoma	N/A
Recruiting	Pilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury NCT06109909	VA Office of Research and Development	N/A
Unknown	Migraine Headache Mitigation Utilizing Avulux NCT06149000	Kaiser Permanente	N/A
Withdrawn	Improving Glare and Visual Comfort for Patients With Visual Impairment NCT05829135	Nova Southeastern University	N/A
Completed	Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention NCT05207865	Pfizer	Phase 4
Completed	Performance and Tolerability of the Medical Device LACRIACT NCT06159569	Laboratórios Baldacci S.A	N/A
Completed	Mindfulness Based Cognitive Therapy Modified for Visual Symptoms (MBCT-vision) NCT04184726	Guy's and St Thomas' NHS Foundation Trust	N/A
Recruiting	Objectively Diagnose and Monitor Treatment of Light Sensitivity NCT03694626	Randy Kardon	N/A
Withdrawn	Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis) NCT02837523	CENTOGENE GmbH Rostock	—
Unknown	Functional MRI Study of Cortical Modifications to Light Stimulation in Patients With Photophobia NCT03464357	University Hospital, Toulouse	N/A
Completed	How Can we Treat Photophobia in Migraine NCT05369910	Medical University of Vienna	N/A
Terminated	Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With M NCT01942486	University of Utah	N/A
Completed	The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study NCT01942564	Ohio State University	—
Completed	Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine NCT01828684	Bradley Katz	N/A
Completed	An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack NCT00330850	ProEthic Pharmaceuticals	Phase 3